Medicamen Organics Ltd

As of November 19, 2025, Medicamen Organ. is considered undervalued with a PE ratio of 9.80, significantly lower than its peers, indicating an attractive valuation despite a year-to-date return of -49.17% compared to the Sensex's 10.18%.

As of November 18, 2025, Medicamen Organ. is fairly valued with a PE ratio of 10.32 and has underperformed significantly with a year-to-date return of -46.47%, raising concerns about its growth prospects compared to peers like Sun Pharma and Cipla.

As of November 17, 2025, Medicamen Organ. is considered undervalued with a PE ratio of 9.84 and an EV to EBITDA of 7.39, despite a year-to-date stock decline of -48.98%, indicating that the market may not fully recognize its potential compared to more expensive peers like Sun Pharma and Divi's Lab.

Medicamen Organ experienced significant financial growth from March 2024 to March 2025, with net sales rising to 38.19 Cr and profit after tax increasing to 4.05 Cr. Key metrics such as operating profit and earnings per share also improved, indicating strong overall performance.

As of November 12, 2025, Medicamen Organ is fairly valued with a PE ratio of 10.36 and has underperformed significantly with a year-to-date stock return of -46.29%, raising concerns about its market position and growth prospects compared to peers like Sun Pharma and Cipla.

As of November 10, 2025, Medicamen Organ. is fairly valued with a PE ratio of 10.23 and an EV to EBIT of 8.80, significantly lower than its peers like Sun Pharma and Divi's Lab, despite a year-to-date return of -46.94% compared to the Sensex's gain of 8.16%.

As of November 4, 2025, Medicamen Organ. is considered overvalued with a PE ratio of 11.91 and an EV to EBITDA of 8.62, significantly underperforming the Sensex with a year-to-date return of -38.22%.

As of November 4, 2025, Medicamen Organ. is considered overvalued with a PE Ratio of 11.91 and poor stock performance, significantly lagging behind peers like Sun Pharma and Cipla, making it an unfavorable investment.

As of November 3, 2025, Medicamen Organ. is fairly valued with a PE ratio of 11.43, but has underperformed the Sensex with a year-to-date return of -40.72%, indicating limited upside potential in the near term.

As of October 16, 2025, Medicamen Organ. is considered overvalued with a PE Ratio of 12.74 and has underperformed the Sensex with a year-to-date return of -33.95%.

As of October 13, 2025, Medicamen Organ. is fairly valued with a PE ratio of 12.51 and an EV to EBITDA of 8.96, making it an attractive investment compared to its peers, despite a recent underperformance of -40.46% against the Sensex.

As of October 10, 2025, Medicamen Organ. is considered overvalued with a PE ratio of 12.83 and an EV to EBITDA of 9.15, showing weaker valuation compared to peers like Sun Pharma and Divi's Lab, despite a recent short-term stock return of 7.82%.

As of October 10, 2025, Medicamen Organ. is considered overvalued with a valuation grade shift to expensive, reflected by a PE Ratio of 12.83, an EV to EBITDA of 9.15, and a -38.93% return over the past year, underperforming compared to peers like Sun Pharma and Dr. Reddy's Labs.

As of October 10, 2025, Medicamen Organ. is considered overvalued with a PE ratio of 12.83, an EV to EBITDA of 9.15, and a ROCE of 12.71%, showing a significant decline in year-to-date returns of -33.49% despite a recent weekly return of 7.82%.

As of 01-October, Medicamen Organics Ltd's stock price is 33.25, up 4.89% today, but it has declined 5.14% over the past week and significantly underperformed over the past month and year. The stock is trading below its moving averages, with a notable drop in investor participation, indicating ongoing challenges despite today's gains.

As of 29-Sep, Medicamen Organics Ltd's stock price has declined to 31.65, down 4.95%, and has underperformed its sector and the broader market significantly. The stock has seen a 41.28% year-to-date decline and a 9.70% drop over the past week, with reduced investor participation.

As of 24-Sep, Medicamen Organics Ltd is priced at 35.05 with no change, having outperformed its sector by 0.45% recently. However, it is trading below all key moving averages and has seen a significant decline in investor participation, with a 14.51% drop over the past month and a 49.50% decline year-over-year, indicating ongoing challenges in maintaining market confidence.

As of 23-Sep, Medicamen Organics Ltd is priced at 35.05 with no change, having significantly underperformed with a year-to-date decline of 34.97%. The stock is trading above its 5-day moving average but below longer-term averages, and there is reduced investor interest indicated by a 62.96% drop in delivery volume.

As of 22-Sep, Medicamen Organics Ltd's stock price is at 35.05, down 1.82%, and has significantly underperformed over the long term with a 34.97% decline year-to-date. Despite a recent positive movement of 3.09% over the past week, investor sentiment remains negative compared to the benchmark Sensex.